

Charline Cl Lasnon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/307647/publications.pdf>

Version: 2024-02-01

43
papers

1,019
citations

471509

17
h-index

434195

31
g-index

46
all docs

46
docs citations

46
times ranked

1324
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in PET/CT Technology: An Update. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 286-301.	4.6	12
2	Artificial intelligence-based PET denoising could allow a two-fold reduction in [18F]FDG PET acquisition time in digital PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3750-3760.	6.4	13
3	Feasibility of Imaging Small Animals on a 360° Whole-Body Cadmium Zinc Telluride SPECT Camera: a Phantom Study. <i>Molecular Imaging and Biology</i> , 2022, 24, 1018-1027.	2.6	1
4	Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2573-2585.	6.4	35
5	A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers. <i>EJNMMI Research</i> , 2021, 11, 11.	2.5	6
6	Revisiting detection of in-transit metastases in melanoma patients using digital 18F-FDG PET/CT with small-voxel reconstruction. <i>Annals of Nuclear Medicine</i> , 2021, 35, 669-679.	2.2	13
7	New PET technologies “embracing progress and pushing the limits. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2711-2726.	6.4	35
8	End-of-treatment ¹⁸ F-FDG PET/CT in diffuse large B cell lymphoma patients: $\hat{\tau}$ SUV outperforms Deauville score. <i>Leukemia and Lymphoma</i> , 2021, 62, 2890-2898.	1.3	4
9	18F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital. <i>Diagnostics</i> , 2021, 11, 1198.	2.6	1
10	Author Gender Inequality in Medical Imaging Journals and the COVID-19 Pandemic. <i>Radiology</i> , 2021, 300, E301-E307.	7.3	35
11	Can someone look after my children while I write this COVID-19 paper?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3751-3752.	6.4	3
12	Upfront F18-choline PET/CT versus Tc99m-sestaMIBI SPECT/CT guided surgery in primary hyperparathyroidism: the randomized phase III diagnostic trial APACH2. <i>BMC Endocrine Disorders</i> , 2021, 21, 3.	2.2	12
13	Women Authors in Nuclear Medicine Journals: a Survey from 2014 to 2020. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262773.	5.0	1
14	More fat, less migration: breast density as a predictor of sentinel lymph node non-visualization in breast cancer. <i>EJNMMI Research</i> , 2021, 11, 112.	2.5	3
15	Diagnostic value of baseline 18FDG PET/CT skeletal textural features in follicular lymphoma. <i>Scientific Reports</i> , 2021, 11, 23812.	3.3	6
16	How fast can we scan patients with modern (digital) PET/CT systems?. <i>European Journal of Radiology</i> , 2020, 129, 109144.	2.6	23
17	Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy. <i>European Radiology</i> , 2020, 30, 4623-4632.	4.5	61
18	Hormonal Receptor Immunochemistry Heterogeneity and 18F-FDG Metabolic Heterogeneity: Preliminary Results of Their Relationship and Prognostic Value in Luminal Non-Metastatic Breast Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 599050.	2.8	13

#	ARTICLE	IF	CITATIONS
19	HYPHYCA: a prospective study in 613 patients conducting a comprehensive analysis for predictive factors of physiological 18F-FDG anal uptake. EJNMMI Research, 2020, 10, 28.	2.5	2
20	Comprehensive analysis of the influence of G-CSF on the biodistribution of 18F-FDG in lymphoma patients: insights for PET/CT scheduling. EJNMMI Research, 2019, 9, 79.	2.5	6
21	Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 421-428.	6.4	27
22	Combining baseline TMTV and gene profiling for a better risk stratification in diffuse large B cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 677-679.	6.4	2
23	Assessment of alteration in liver 18F-FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 941-950.	6.4	16
24	Reply to: "All that glitters is not gold" new reconstruction methods using Deauville criteria for patient reporting. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 878-881.	6.4	5
25	Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 699-711.	6.4	37
26	Does PET Reconstruction Method Affect Deauville Score in Lymphoma Patients?. Journal of Nuclear Medicine, 2018, 59, 1049-1055.	5.0	22
27	Implications of reconstruction protocol for histo-biological characterisation of breast cancers using FDG-PET radiomics. EJNMMI Research, 2018, 8, 114.	2.5	23
28	Reply to the Letter to the Editor from Peters et al: On the use of the liver as a reference organ for Deauville scoring in lymphoma patients and how it may be affected by liver steatosis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2233-2234.	6.4	1
29	Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction. Annals of Nuclear Medicine, 2017, 31, 125-134.	2.2	33
30	Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs). EJNMMI Research, 2017, 7, 30.	2.5	27
31	EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 17-31.	6.4	206
32	EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program. EJNMMI Physics, 2017, 4, 17.	2.7	14
33	Does PET SUV Harmonization Affect PERCIST Response Classification?. Journal of Nuclear Medicine, 2016, 57, 1699-1706.	5.0	31
34	18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2324-2335.	6.4	45
35	Patient's weight: a neglected cause of variability in SUV measurements? A survey from an EARL accredited PET centre in 513 patients. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 197-199.	6.4	13
36	Quantifying and correcting for tail vein extravasation in small animal PET scans in cancer research: is there an impact on therapy assessment?. EJNMMI Research, 2015, 5, 61.	2.5	7

#	ARTICLE	IF	CITATIONS
37	NEMA NU 4-Optimized Reconstructions for Therapy Assessment in Cancer Research with the Inveon Small Animal PET/CT System. <i>Molecular Imaging and Biology</i> , 2015, 17, 403-412.	2.6	13
38	The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma: focus on the Deauville criteria. <i>Haematologica</i> , 2014, 99, e84-e85.	3.5	22
39	Diuretic 18 F-FDG PET/CT for therapy monitoring in urothelial bladder cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1818-1819.	6.4	6
40	Contrast-enhanced small-animal PET/CT in cancer research: strong improvement of diagnostic accuracy without significant alteration of quantitative accuracy and NEMA NU 4's 2008 image quality parameters. <i>EJNMMI Research</i> , 2013, 3, 5.	2.5	9
41	Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 985-996.	6.4	107
42	Impact of Point Spread Function Reconstruction on Thoracic Lymph Node Staging With 18F-FDG PET/CT in Non-Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2012, 37, 971-976.	1.3	53
43	¹⁸ F-FDG imaging can accurately distinguish between mature teratoma and necrosis in 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 323-333.	6.4	12